JATT III Acquisition Corp
JTTT · Nasdaq · Healthcare
NO ACTION REQUIRED
Nothing required today
No redemption election is on file for this SPAC. A date appears here the day one is filed.
Cash per share
Held for each public share, as last filed.
Last close
Daily close · 9 Sept 2026
SpacBrain’s read
Floor not confirmed
No redemption window has closed — but no dated redemption election is on file for this name either, so we cannot show you a date to act by.
What we do have: no window has closed, and no company deadline is on file either. The full chain of evidence is under Evidence.
Change on the last daily close+0.8% day
That is $1.10 above the $10.00 of cash held per share as last filed. Everything above the cash is what the market thinks the deal is worth, and redemption does not protect it.
In plain terms
- What it is
- A SPAC from JATT (biotech serial), listed on Nasdaq in August 2026.
- What it's doing now
- It is still looking: no purchase has been announced, and no deadline for agreeing one is on file with us.
- What you should know
- We have no filed date on which you could claim the cash back, so we cannot tell you a day to act by. That is a gap in the public record, not a statement that the right has gone.
At a glance
- Where it stands
- Searching
- Merging with
- No target announced — still searching.
- Industry
- Healthcare
- What it set out to buy: Healthcare
- Deal value
- not stated in the filings we hold
- Price vs cash floor
- $11.10 vs $10.00
- $1.10 above the last filed cash held for you
- Cash left in trust
- not yet extracted into a snapshot — the filings below may state it
- IPO
- 26 August 2026
- size not on file · 100.0% of each $10 unit into trust
- Headquarters
- 153 CENTRAL AVENUE C/O 56, WESTFIELD, NJ, 07091
- registered in the Cayman Islands
- Lead underwriter
- Guggenheim Securities, LLC
- Key officers
- Fernandez Nicholas (Director) · Sidhu Someit (CEO and Chairman) · Staral Christopher (Director)
- Listed securities
- JTTT common · JTTT common $11.19
As last filed — the filing date is not recorded.
- vs last filed NAV
- 11.0%above cash
- $10.00
Measured against the last filed cash figure. No accrued estimate is published for this SPAC, so no second reading is shown.
Nothing dated is on file. That is an absence in our record, not a statement that nothing is coming.
Yield to redemption
No dated redemption window on file — no yield to compute.
We hold no redemption election for this SPAC and no dated event of any kind — there is nothing to measure a yield to. An unsourced date would make the yield look filed when it is not.
What is protecting this price
The reasoning behind the verdict above, in the order the filings establish it.
- No dated redemption election is on file for this name. That is an absence in the record, not proof that the right has gone — but it does mean this page cannot tell you a day to act by.
- Cash held in trust is $10.00 per share as last filed. That is the figure a redemption pays out at, plus whatever interest the trust earns between the filing and the window.
What has happened, and what is coming
1 dated milestoneEvery dated step from the day it listed to the next date you may have to act on. Where you have to do something, the day your broker needs the instruction is marked too.
- 26 August 2026IPOpassed
IPO size not on file
The score
deterministic, from filed fieldsOne number for the shape of the bet: how much upside you are getting per unit of downside. It is arithmetic over filed fields, not a rating and not advice — and it is the same number this SPAC carries on the leaderboard, the screener and the deal list, because all four read one engine.
11.0% premium to the last filed trust — capital at risk
The blend is trust discount (40 points), deal stage (30), sponsor track record (18) and time to catalyst (12). Every input is a real sourced field; where one is missing, confidence drops rather than a number being invented.
The company
from SEC filingsRead the full profile
A planned $60 million SPAC — the third vehicle from the JATT team, serial sponsors of biotech SPACs — whose August 2026 SEC prospectus offers 6 million ordinary shares to pursue a healthcare business, with a primary emphasis on biotechnology and the wider life sciences. Not yet listed; no ticker or target.
Material findings
from the full read of every filingEvery document this company files gets read whole — body and exhibits. These are the ones the read flagged as material, newest first, each citing its filing.
This filing establishes the final capitalization and trust value ($10.00 per share) for public shareholders, defining the baseline for potential redemption values and the funds available for a future business combination search.
This filing confirms the capital raise and initial governance structure, establishing the 24-month deadline by which investors must track deal progress or prepare for potential redemption of their $10 per share trust value.
This is the foundational document for a new SPAC led by Dr. Someit Sidhu, a serial biotech/SPAC entrepreneur with a track record (JATT I closed with Zura Bio in 2023; JATT II has a pending deal with Talawar). The SPAC is targeting healthcare/life sciences. The non-binding PIPE commitments provide a capital-stack signal. The trust per-share is $10.00. The 24-month clock starts at IPO closing. The structure includes a 20% shareholder-redemption cap per group, a $10.00 per-share trust floor guaranteed by the sponsor, and standard lock-ups (180 days for founder shares, 30 days for private placement shares).
This is the foundational filing for a new SPAC IPO. It confirms the terms investors will face. The trust is $10.00, but the redemption mechanics and the 20% redemption cap are significant structural features for tracking. The document underscores heavy dilution potential (sponsor paid $0.0145 per founder share) and outlines sponsor/management incentives to complete a deal. The focus on healthcare/biotech/life sciences is stated. The lack of a specified maximum redemption threshold and the quorum voting dynamics could allow a deal to close with minimal public shareholder support.
Filings
live EDGAR feedEverything this company has filed with the SEC recently, newest first, each with a plain summary of what changed and why it matters.
What changed: JATT III Acquisition Corp filed an 8-K on September 2, 2026, confirming the consummation of its IPO on August 27, 2026, which sold 6,900,000 ordinary shares at $10.00 per share for $69,000,000 in gross proceeds, including the full exercise of the underwriters' over-allotment option. Simultaneously, the Company completed a private placement of 234,000 shares to JATT Ventures III L.P. for $2,340,000, resulting in a total of $69,000,000 deposited into the trust account as of August 27, 2026. Why it matters: This filing establishes the final capitalization and trust value ($10.00 per share) for public shareholders, defining the baseline for potential redemption values and the funds available for a future business combination search.
What changed: JATT III Acquisition Corp consummated its IPO on August 27, 2026, selling 6,900,000 ordinary shares at $10.00 per share for $69,000,000 in gross proceeds, and simultaneously sold 234,000 private placement shares to sponsor JATT Ventures III L.P. for $2,340,000. The filing appoints four independent directors (Verender S. Badial, Christopher Staral, Arjun Goyal, Jonathon Kluft) and establishes a trust account with net proceeds of $69,000,000, subject to redemption if a business combination is not completed within 24 months. Why it matters: This filing confirms the capital raise and initial governance structure, establishing the 24-month deadline by which investors must track deal progress or prepare for potential redemption of their $10 per share trust value.
Show the other 8 filings
What changed: S-1 registration statement for a $60 million (up to $69 million with over-allotment) SPAC initial public offering of 6,000,000 ordinary shares (up to 6,900,000) at $10.00 per share, with no warrants sold to the public. JATT III Acquisition Corp, a newly-formed blank check company, filed the initial S-1 for its IPO on August 7, 2026. The filing formally sets forth the offering terms: $10.00 per share, a 24-month deadline to complete a business combination (which may be extended with a shareholder vote), an initial trust of $60 million ($69 million with over-allotment), a 20% founder-share structure (sponsor paid ~$0.0145/share), and no public warrants. The sponsors have secured non-binding indications of interest for up to $45 million in PIPE financing from AI Biotechnology ($30 million) and Vianti Capital ($15 million) to close concurrently with a business combination. Why it matters: This is the foundational document for a new SPAC led by Dr. Someit Sidhu, a serial biotech/SPAC entrepreneur with a track record (JATT I closed with Zura Bio in 2023; JATT II has a pending deal with Talawar). The SPAC is targeting healthcare/life sciences. The non-binding PIPE commitments provide a capital-stack signal. The trust per-share is $10.00. The 24-month clock starts at IPO closing. The structure includes a 20% shareholder-redemption cap per group, a $10.00 per-share trust floor guaranteed by the sponsor, and standard lock-ups (180 days for founder shares, 30 days for private placement shares).
What changed: DRS — Draft registration statement on Form S-1 filed confidentially with the SEC on July 17, 2026. This is a preliminary prospectus for the initial public offering of JATT III Acquisition Corp, a blank-check company. Initial confidential filing of the registration statement. Establishes the terms of the IPO: 6,000,000 ordinary shares at $10.00 per share, aiming to raise $60,000,000 ($69,000,000 if over-allotment exercised). Investors do not receive warrants. The trust will hold $10.00 per share. The sponsor (JATT Ventures III L.P.) commits to purchase 300,000 private placement shares ($3,000,000) simultaneously. The completion window is 24 months from the closing of the offering, with no mandatory redemption threshold. Redemption rights exist, but shareholders holding more than 20% of the shares are restricted from redeeming if the company seeks a shareholder vote. The filing also details the management team, conflicts of interest and prior SPAC experience, including JATT I (Zura Bio) and JATT II (Talawar Tx). Why it matters: This is the foundational filing for a new SPAC IPO. It confirms the terms investors will face. The trust is $10.00, but the redemption mechanics and the 20% redemption cap are significant structural features for tracking. The document underscores heavy dilution potential (sponsor paid $0.0145 per founder share) and outlines sponsor/management incentives to complete a deal. The focus on healthcare/biotech/life sciences is stated. The lack of a specified maximum redemption threshold and the quorum voting dynamics could allow a deal to close with minimal public shareholder support.
The sponsor
The people who set this company up, what they have done before, and the advisers around the deal.
At-risk capital: $2.3M — 225,000 private placement shares, bought at the IPO and worthless if the company liquidates. This is what the sponsor itself loses if no deal closes. per the prospectus (S-1 0001213900-26-086864)
Deal completion: 1/1 resolved vehicles closed a deal (100%); 0 liquidated, 0 terminated. Gated ×0.93 by measured post-close quality (43/100): closing deals that ended below trust value is not a completed job, so only 93% of the completion credit is earned. Full credit resumes at outcome quality 50/100 (the median deSPAC ending at trust value); the gate can never exceed 1×. Small sample — the shrink below keeps this near neutral.
Mixed record · low confidence
- JATT Acquisition Corp · 2021→ Zura BioZURACompleted
JATT — biotech serial led by Dr. Someit Sidhu. Prior-vehicle track record (SEC-verified via formerNames): JATT Acquisition Corp COMPLETED → Zura Bio (ZURA, Nasdaq, still listed). Current vehicle JATT (in-deal) plus one searching. Net: 1 completed deSPAC (listed). Sources: SEC EDGAR submissions API (formerNames) + full-text search, efts.sec.gov. — research profile — JATT is a biotech-focused serial SPAC sponsor led by Dr. Someit Sidhu, a serial biotech entrepreneur and former McKinsey consultant who trained at Oxford Medical School. Sidhu has founded or co-founded multiple biotech ventures including Khanda Therapeutics, Izana Bioscience (sold to Roivant in 2020), Pathios Therapeutics, and Akaza Bioscience. The JATT platform has now produced at least three vehicles: JATT Acquisition Corp (JATT I), JATT II Acquisition Corp (JATT II), and a filed JATT III. The sponsor entity for JATT II is JATT Ventures II L.P. The management team is rounded out by CFO Nicholas Fernandez, a seasoned finance executive with prior stints as COO/CFO of Athanor Capital and CFO of Jefferies' Asset Management and Alternative Investments divisions, along with a board featuring Verender S. Badial (former MD in Equity Capital Markets at Societe Generale and ABN AMRO Rothschild, with 48 public market deals to his credit), Arjun Goyal (founder of Vianti Capital, co-founder of Vida Ventures with $4B in M&A), Dr. Jonathon Kluft (former VP at Roivant Sciences, instrumental in forming Immunovant, Urovant, and Pulmovant), and Christopher Staral (founder/CIO of Triple Helix Investments, former biotech equity research at Goldman Sachs). Guggenheim Securities has served as sole bookrunner across the JATT II offering. JATT I completed its business combination with Zura Bio Limited in March 2023, a deal with a $215 million pro forma enterprise value. The transaction was originally structured to deliver up to $189 million in gross proceeds ($139 million from trust assuming no redemptions, plus $50 million in PIPE and forward purchase commitments), but Zura Bio ultimately netted only approximately $65 million in gross cash proceeds, implying substantial redemptions by public shareholders. The post-de-SPAC performance was poor: Zura Bio (ZURA) traded down approximately 43% from the $10 offer price, according to Renaissance Capital. Sidhu served as Zura Bio's CEO from the deal's close through April 2024 before transitioning to a director role, and Badial served as CFO of Zura Bio post-combination, meaning the team has direct experience operating a public biotech through a challenging post-SPAC period. JATT II raised $60 million in its April 2026 IPO, pricing 6 million shares at $10.00 as a stock-only SPAC with no warrants or rights attached, a structure that aligns sponsor and shareholder interests more tightly than traditional unit offerings. The vehicle traded at a premium post-IPO, reaching approximately $13.00 and delivering a +30% return from IPO with a +5% first-day pop. In June 2026, JATT II announced a definitive business combination with Talawar Therapeutics, a company developing bispecific antibodies for immunology and inflammatory diseases. The deal includes a $225 million oversubscribed PIPE at $10.00 per share alongside the $60 million in trust, for $285 million in expected gross proceeds assuming no redemptions. The PIPE syndicate includes blue-chip biotech investors Access Biotechnology, Bain Capital Life Sciences, and RA Capital. Talawar's lead asset, TALA-125 (an anti-IL-13 x anti-IL-18 bispecific for atopic dermatitis), is not expected to enter the clinic until 1Q 2027, with interim Phase 1 data in 4Q 2027 and Phase 2b proof-of-concept data only anticipated in 2H 2028. The stock surged approximately 13% on the deal announcement. The JATT track record presents a mixed picture. On one hand, the team has demonstrated an ability to source…
Full sponsor record →Deal team — named in the prospectus
- Guggenheim Securities, LLCLead-left
Read from this SPAC’s own prospectus; the arrow opens the filing. Firms link to their full mandate record.
The record
The reference detail — how the shares were structured at listing, how thinly they trade, and where the company is registered.
Show the reference detail
Unit structure
from S-1 0001213900-26-086864
Trading & liquidity
Thin book — limit orders only; a position can be hard to exit outside a redemption window.
Company profile
Directors & officers
- Fernandez NicholasDirector
- Sidhu SomeitCEO and Chairman
- Staral ChristopherDirector
- GOYAL ARJUNDirector
- Kluft JonathonDirector
- Badial Verender S.Director
Sources on file
harvested pages, kept in fullEvery public page we have read about this company, stored in full so a source can never go missing.
Show the sources
38 full SEC filing texts archived — searchable, never lost.
- Vault note — JTTT (JATT III Acquisition Corp)
vault-note · /vault/tickers/JTTT
- Vault note — CIK2145659 (JATT III Acquisition Corp)
vault-note · /vault/tickers/CIK2145659
In plain English
tap a term to open itEvery piece of jargon this page could have used, and what it actually means.
Open the plain-English guide
No floor / floorlessthe cash guarantee is gone — the price is unprotected
A SPAC's downside protection is not the cash in trust; it is your right to demand that cash. Once the redemption window closes, the cash stays with the company and the share can trade anywhere.
Redemption deadlinethe last day to hand shares back for cash
Set by the filing that calls the meeting. Tender after it and the company is under no obligation to pay you the trust value.
Broker action datethe day your broker needs the instruction — earlier than the official date
Brokers batch redemption instructions to the transfer agent, so the practical cutoff is roughly two business days before the published deadline. This is the date that actually costs people the floor.
Cash in trust / trust per sharethe cash the company is holding for each public share
Filed quarterly in the 10-Q's XBRL. It earns interest between filings, so the figure on a given day is slightly higher than the last filed one — where we show that we label it an estimate.
Trust discountbuying below the cash held for you
Only meaningful while a redemption right exists. On a floorless name the same arithmetic is not a discount, it is the market pricing distress, and this product will not call it a yield.
Dilutionhow much of the company new shares take from you
Sponsor promote, PIPE shares, warrants and rights all issue stock that did not pay $10 for it. The headline deal value is before that; the effective value is after.
Pro-forma equitywhat the company is valued at once the deal closes
The combined company's equity value assuming the announced terms and the redemptions that have actually happened.
ARShow much upside you get per unit of downside
SpacBrain's asymmetric-return score. It is deterministic — the same inputs always produce the same number — and it is capped, not zeroed, when the floor is gone.
De-SPACthe day the SPAC becomes the real company
The shares stop being a claim on a pot of cash and start being equity in an operating business. Roughly 80% of recent de-SPACs traded below $10 within a year.
Outside datethe contractual long-stop for closing the deal
A deadline between the SPAC and its target, not between the SPAC and you. It confers no right to cash, which is exactly why it must never be counted as a redemption window.
Accession numberthe SEC's unique id for one filing
Every figure on this page carries the accession of the filing that states it, so you can open the primary document rather than trust us.
Accreted NAV (estimate)the last filed cash figure, plus the interest it should have earned since
A model, not a filing: last filed value compounded at the 3-month T-bill for the days elapsed. Always shown in italic with the word estimate, and never printed beside a filed number without it.
Ask the brain
from its filingsData provenance & audit trail3 internal entries
Written by SpacBrain’s data agents whenever a figure is captured, corrected or flagged, and kept verbatim so every number on this page can be traced back to the filing that states it. This is a running log, not the current record: an early entry may be superseded by a later correction — the panels above always hold the current values.
registered from S-1 — pre-listing, ticker TBD, VERIFY it is a SPAC
trustPerShare = initial trust per unit as priced (S-1 0001213900-26-086864) — no 10-Q trust reading on file yet
CIK2145659 → JTTT from SEC submissions